Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 1
1998 3
1999 1
2000 1
2001 1
2002 2
2003 3
2004 6
2005 4
2006 5
2007 7
2008 7
2009 6
2010 5
2011 7
2012 10
2013 9
2014 12
2015 16
2016 16
2017 14
2018 19
2019 10
2020 23
2021 26
2022 17
2023 17
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

212 results

Results by year

Filters applied: . Clear all
Page 1
[What should we remember from 2020?].
Bay JO, Andre T, Bouleuc C, Gandemer V, Magne N, Orbach D, Pellier I, Penel N, Rodrigues M, Thariat J, Thiery-Villemin A, Wisley M, L'Allemain G, Robert J; Comité de rédaction du Bulletin du cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2021 Jan;108(1):55-66. doi: 10.1016/j.bulcan.2020.12.002. Epub 2021 Jan 6. Bull Cancer. 2021. PMID: 33419531 Review. French.
[A 2021 inventory in oncology news].
Bay JO, Bouleuc C, Firmin N, Gandemer V, Magne N, Orbach D, Penel N, Rodrigues M, Thiery-Vuillemin A, Wislez M, L'Allemain G, Sabatier R, Robert J; comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2022 Jan;109(1):8-19. doi: 10.1016/j.bulcan.2021.12.003. Epub 2021 Dec 31. Bull Cancer. 2022. PMID: 34980367 Review. French.
[A 2022 inventory in oncology news].
Bay JO, Bouleuc C, Caux C, Delom F, Firmin N, Gandemer V, L'Allemain G, Magné N, Orbach D, Robert J, Rodrigues M, Sabatier R, Thiery-Vuillemin A, Wislez M; Comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2023 Jan;110(1):19-31. doi: 10.1016/j.bulcan.2022.12.002. Epub 2022 Dec 16. Bull Cancer. 2023. PMID: 36529541 Review. French.
[A 2023 inventory in oncology news].
Bay JO, Auberger B, Bouleuc C, Cohen R, Delom F, Firmin N, Gandemer V, L'Allemain G, Magne N, De Nonneville A, Orbach D, Pellier I, Rodrigues M, Wislez M; pour le comité de rédaction du Bulletin du Cancer. Bay JO, et al. Among authors: gandemer v. Bull Cancer. 2024 Jan;111(1):18-32. doi: 10.1016/j.bulcan.2023.12.003. Epub 2024 Jan 5. Bull Cancer. 2024. PMID: 38184423 Review. French.
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation.
Ruggeri A, De Wreede LC, Müller CR, Crivello P, Bonneville EF, Petersdorf EW, Socié G, Dubois V, Niittyvuopio R, Peräsaari J, Yakoub-Agha I, Cornelissen JJ, Wieten L, Gedde-Dahl T, Forcade E, Crawley CR, Marsh SGE, Gandemer V, Tholouli E, Bulabois CE, Huynh A, Choi G, Deconinck E, Itäla-Remes M, Lenhoff S, Bengtsson M, Johansson JE, Van Gorkom G, Hoogenboom JD, Vago L, Rocha V, Bonini C, Chabannon C, Fleischhauer K. Ruggeri A, et al. Among authors: gandemer v. Haematologica. 2023 Feb 1;108(2):645-652. doi: 10.3324/haematol.2021.280055. Haematologica. 2023. PMID: 35546480 Free PMC article. No abstract available.
Real-world use of defibrotide for veno-occlusive disease/sinusoidal obstruction syndrome: the DEFIFrance Registry Study.
Mohty M, Blaise D, Peffault de Latour R, Labopin M, Bourhis JH, Bruno B, Ceballos P, Detrait M, Gandemer V, Huynh A, Izadifar-Legrand F, Jubert C, Labussière-Wallet H, Lebon D, Maury S, Paillard C, Pochon C, Renard C, Rialland F, Schneider P, Sirvent A, Asubonteng K, Guindeuil G, Yakoub-Agha I, Dalle JH. Mohty M, et al. Among authors: gandemer v. Bone Marrow Transplant. 2023 Apr;58(4):367-376. doi: 10.1038/s41409-022-01900-6. Epub 2022 Dec 23. Bone Marrow Transplant. 2023. PMID: 36564486 Free PMC article.
Prognostic value and oncogenic landscape of TP53 alterations in adult and pediatric T-ALL.
Simonin M, Andrieu GP, Birsen R, Balsat M, Hypolite G, Courtois L, Graux C, Grardel N, Cayuela JM, Huguet F, Chalandon Y, Le Bris Y, Macintyre E, Gandemer V, Petit A, Rousselot P, Baruchel A, Bouscary D, Hermine O, Boissel N, Asnafi V. Simonin M, et al. Among authors: gandemer v. Blood. 2023 Mar 16;141(11):1353-1358. doi: 10.1182/blood.2022017755. Blood. 2023. PMID: 36599110 Free article. No abstract available.
Therapeutic drug monitoring of imatinib - how far are we in the leukemia setting?
Buhl Rasmussen AS, Andersen CL, Weimann A, Yang T, Tron C, Gandemer V, Dalhoff K, Rank CU, Schmiegelow K. Buhl Rasmussen AS, et al. Among authors: gandemer v. Expert Rev Clin Pharmacol. 2024 Mar;17(3):225-234. doi: 10.1080/17512433.2024.2312256. Epub 2024 Feb 12. Expert Rev Clin Pharmacol. 2024. PMID: 38345044 Review.
Prognostic impact of RUNX1 mutations and deletions in pediatric acute myeloid leukemia: results from the French ELAM02 study group.
Lew-Derivry L, Marceau-Renaut A, Fenwarth L, Cuccuini W, Ballerini P, Ferreboeuf M, Guilmatre A, Petit A, Gandemer V, Rialland F, Schneider P, Michel G, Bertrand Y, Baruchel A, Preudhomme C, Leverger G, Lapillonne H. Lew-Derivry L, et al. Among authors: gandemer v. Leukemia. 2023 Aug;37(8):1723-1726. doi: 10.1038/s41375-023-01931-y. Epub 2023 Jun 16. Leukemia. 2023. PMID: 37328541 Free PMC article. No abstract available.
212 results